(Q38002127)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Fermín Sánchez de Medina

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Luis Bujanda

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Marta R. Romero

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Beatriz Castaño

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Olga Martinez-Augustin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Rosario Del Moral-Avila

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Oscar Briz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

1 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

published in

Drug Metabolism Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

148-172

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers.

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Malignant colorectal polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Adjuvant therapy of colorectal cancer. Why we still don't know

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Primary prevention of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Role of organic cation transporters in the renal secretion of nucleosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Estrogen plus progestin and colorectal cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Folic Acid for the Prevention of Colorectal Adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

The staging of colorectal cancer: 2004 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Mature results from three large controlled studies with raltitrexed ('Tomudex').

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Prediction of broad spectrum resistance of tumors towards anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Metastatic colorectal cancer: from improved survival to potential cure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Calcium and vitamin D. Their potential roles in colon and breast cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Expression of metallothionein in colorectal cancers and synchronous liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Expression of the human copper influx transporter 1 in normal and malignant human tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Diagnosis and management of dysplasia in patients with inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Prostaglandins and cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Should preoperative or postoperative therapy be administered in the management of rectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

ATP-binding cassette, subfamily G (ABCG family).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Markers of drug resistance in relapsing colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Inactivating mutation of the pro-apoptotic gene BID in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

The role of DNA mismatch repair in cisplatin mutagenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Aspirin and folic acid for the prevention of recurrent colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

c-FLIP inhibits chemotherapy-induced colorectal cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Diet and cancer prevention: the roles of observation and experimentation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

PTEN status in advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Drug insight: aminosalicylates for the treatment of IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Current options for the management of rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Fluorouracil: biochemistry and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Statins and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Optimal delivery of cytotoxic chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Folate intake and colorectal cancer risk: a meta-analytical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Preoperative versus postoperative chemoradiotherapy for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

The anti-proliferative potency of celecoxib is not a class effect of coxibs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Does butyrate protect from colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Topoisomerase II gene mutations in tumors and tumor cell lines with microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Combinations of 5-fluorouracil with UCN-01 or staurosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Nutritional interventions in cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Capecitabine as adjuvant treatment for stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Management of early rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Calcium plus vitamin D supplementation and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Recombinant factor VIIa in the management of pulmonary hemorrhage associated with metastatic choriocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Susceptibility Genetic Variants Associated With Colorectal Cancer Risk Correlate With Cancer Phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Inhibitor of Apoptosis (IAP) Proteins: Novel Insights into the Cancer-Relevant Targets for Cell Death Induction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602532.2011.638303

10.3109/03602532.2011.638303

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22497631%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference